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direct and indirect costs of patients with AF-related stroke in China, producing 
an average cost per patient per year and the economic burden of the whole AF-
related stroke Chinese population. METHODS: A cost-of-illness analyses was 
performed. Prevalence data on AF-related stroke for the Chinese population was 
collected from literatures. An observational retrospective study was conducted 
to collect the economic data. We recruited 156 patients diagnosed with AF and 
stroke in Beijing, Shanghai and Guangzhou between October 2012 and December 
2012. Patients or their carers were interviewed about resource utilization and 
absenteeism from work in the past year. Direct medical costs included 
outpatient visit, hospitalization, ambulatory, drug, diagnostic tests, and 
physiotherapy costs. Indirect costs were estimated using a human capital 
approach. All costs referred to 2011. RESULTS: Among 156 patients with AF-
related stroke, 59.35% were male and the mean age was 67.9±30.2 years. 98.0% 
patients have at least one kind of health insurance. From the societal 
perspective, total costs per patient over 1 year amounted to Chinese Yuan (CNY) 
25538 (median: CNY13342, IQR: CNY7662-CNY 38714), with direct costs 
accounting for 94.2% and indirect costs for 5.8% of the total. And for the direct 
costs, the informal care costs were CNY9162. The drug costs were CNY6293. 
Based on the prevalence of AF and AF-related stroke in China from literatures, 
there was about 0.968 million patients of AF-related stroke. Costs for the nation 
are estimated at CNY24.7 billion per year. CONCLUSIONS: The economic burden 
of AF-related stroke in China is considerable. The primary burden on patients 
was due to informal care and drugs.  
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OBJECTIVES: To estimate the costs-of-disease and direct cost components of 
DVT and its consequences including pulmonary thromboembolism (PTE), 
pulmonary hypertension (PH) and post-thrombotic syndrome (PTS), in Turkish 
setting. METHODS: A panel consisting of experts on cardiology, hematology, 
pulmonology and cardiovascular surgery, held a meeting to discuss the disease 
management processes of DVT, PE, PH and PTS. They reviewed the global and 
local literature and guidelines, and also they discussed the spectrum of local 
clinical practices that are performed frequently. All cost components, including 
medications, surgical treatment, hospitalization, out-patient follow-up 
procedures and rehabilitation services were reviewed. September 2012 local 
prices for medications and procedures were used as sources. Mid-2012 USD 
currency rate was used. RESULTS: The cost of acute management of DVT was 
estimated as 253 USD/event. When PE was added, this amount increased to 964 
USD/event (60% of the total cost originated from the hospital stay). The cost of 
PH was studied for acute stage and maintenance health care. The cost of acute 
management of PH was calculated as 1,197 USD. The annual cost of PH was 
estimated as 27,430 USD/year. The sources of 63% and 99.6% of the total cost 
were pharmacologic treatment, for acute stage and maintenance, respectively). 
The costs of PTS, for the first and further years, were 602 USD/year and 543 
USD/year (55% and 60% non-pharmacologic treatment cost, respectively). 
CONCLUSIONS: The cost of DVT is quite low, but when the short-term or long-
term complications are taken into consideration, the economic impact of DVT 
gets well significant. Therefore, the contribution of these conditions should not 
be ignored when modeling the disease management in DVT.  
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OBJECTIVES: Though the burden of illness (BOI) in Atrial Fibrillation (AF) is 
unknown in China, reports from developed countries demonstrated that BOI in 
AF is significant. This study is to analyze the economic burden of AF in China. 
METHODS: A systematic review of studies on AF was conducted in both English 
and Chinese databases from 2000 to 2012. Epidemiologic and economic data 
were abstracted to analyze the two key measures of BOI in AF: the Disability 
Adjusted life Year (DALY) loss in AF and the BOI in stroke attributable to AF. 
RESULTS: The BOI in stroke attributable to AF was RMB 4.9 billion annually of 
which 89% was consumed by the patients above 60. The DALYs loss in AF 
amounts to 4,599,687 in total for the population above 30, which outstrips the 
DALYs loss in hypertensive heart disease (3,348,925) and is very close to the 
DALYs loss in diabetic mellitus (4,769,127). The patients with the age below 60 
contribute to 31% of the total DALYs loss. The DALYs loss in male is more than 
the loss in female (55% vs. 45%). The average DALYs loss increases with age in 
the whole lifetime. Stroke was confirmed as the leading contributor to the DALYs 
loss among AF patients, accounting for 44.21% followed by heart failure (38.14%) 
and myocardial infarctions (17.65%). CONCLUSIONS: The BOI in AF in China is 
considerably significant. Stroke is the driver of BOI in AF in China. The average 
DALYs loss of AF attributable to stroke is higher than the average DALYs loss of 
nonfatal stroke in the US (60-69 years old). As the treatment rate of AF is fairly 
low with little compliance to clinical guidelines, it becomes critical to increase 
the awareness of AF and its appropriate management to restore the sinus 
rhythm and reduce consequent stroke.  
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OBJECTIVES: Heart Failure (HF) represents the most costly condition for the 
Medicare population and one of the most common reasons for admission to US 
Hospitals. This study sought to quantify the actual hospital costs for these 
admissions looking at different diagnoses and varying severities. METHODS: 
Using the Premier hospital database, admissions from year 2010 were included if 
they met the following criteria: (a) one or more inpatient admission(s) with an 
International Classification of Diseases, Ninth Revision (ICD-9) primary diagnosis 
code of HF (both chronic and acute HF) and (b) Diagnosis-Related Group (DRG) 
Codes 291-Complications and Comorbidities, 292-Comorbidities or 293-Without 
any Complications and Comorbidities. Patients with an implantable cardiac 
device (e.g. ICD, CRT-D) were excluded. HF admissions were analyzed by DRG. 
Summary statistics were generated for the cost to the hospital overall and for 
each DRG code. RESULTS: A total of 592,279 inpatient admissions with a HF 
Diagnosis code were initially identified; 483,297 were excluded due to evidence of 
a device and/or a lack of HF-related DRG, leaving 108,982 admissions. Of the 
admissions that met the criteria, 44% were classified as DRG 291, 36% DRG 292, 
and 20% DRG 293. Mean costs were $8184 (SD $8,015; median $6140; first quartile 
(Q1) $3989, third quartile (Q3) $9691). Total costs of an admission were 51% fixed 
and 49% variable. Mean Length-of-Stay for admissions was 4.92 days (SD 4.74; 
median 4.00; Q1 2.00, Q3 6.00). Looking at DRGs separately, DRG 291 had the 
highest mean cost $10,558 (SD $10,033.6), followed by 292 $7,017 (SD $5,728) and 
293 $5,067 (SD $4,091). CONCLUSIONS: The cost of a HF hospitalization typically 
exceeded the average reimbursement provided by Medicare which in 2010 was 
$8245, $5947, and $3917 for DRGs 291, 292, and 293, respectively. Heart Failure is 
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OBJECTIVES: Acute Coronary Syndromes (ACS) often occurs in working-age 
individuals. Limited data exist on the burden of ACS on employees. We 
attempted to determine the total burden of illness, including the direct and 
indirect costs associated with ACS for employees and their dependents. 
METHODS: Medical and pharmacy claims (IMS LifeLink data) along with short 
term disability (STD) and long term disability (LTD) claims (Integrated Benefits 
Institute’s Health and Productivity Benchmarking Database) from 2007-2010 were 
analyzed. Indirect cost analyses consisted of work days lost and wage 
replacement costs for the employers. Direct costs consisted of total all-cause and 
ACS related health costs for those newly diagnosed with ACS in the 12 month 
period following diagnosis. To make direct and indirect costs comparable 
between the two databases, all health care cost estimates were weighted by 
analytic weights derived from age and gender distributions of both datasets. 
RESULTS: A total of 37,340 employees had STD or LTD claims for ACS. The 
majority (77.4%) was male; 94% were less than 65 years of age. Employees with 
ACS had on average 60.2±SE:0.29 STD and 397.9±SE:8.09 LTD days per disability 
incident. For employers, the estimated per claim productivity loss for STD and 
LTD were $7,943±SE:39.7 and $52,473±SE:1,114, respectively. Total annual ACS 
health care costs were $8,170±SE:106. Hospitalizations accounted for 75% of total 
annual ACS health costs. Out of the total number of employees (n=29,100), 36% 
had one or more hospitalizations for ACS. When examining this specific cohort 
of patients hospitalized for ACS, the mean total annual ACS health care costs per 
patient more than doubled ($18,899±SE: 253) CONCLUSIONS: These data 
demonstrate that ACS imposes a substantial economic burden on employees. 
Long term productivity losses and disability costs are significant for employers. 
ACS related hospitalizations represent a large portion of total medical costs.  
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OBJECTIVES: Identify the direct costs in angioplasty patients in private hospitals 
in Brazil. METHODS: It was selected patients from 3 (three) Brazilian states in the 
same operator who underwent angioplasty at private hospitals present in Orizon 
database. Parallely was followed the consumption of these medications during 
the same period by PBM (Pharmaceutical Benefit Management). RESULTS: A total 
of 196 patients were identified in a predominantly male population (76%) and 
above 59 years of age (65%) who underwent angioplasty and subsequently 
consumed drugs via PBM. We found that the average expenditure per patient 
with angioplasty with or without stenting in private hospitals corresponds to 
5579.07 USD, while spending only with prosthesis corresponded to 13% of the 
drive. CONCLUSIONS: The treatment of coronary stenoses does not account only 
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surgical procedures, but also the administration of medicines to control lipids, 
blood pressure, antidepressants and even hypoglycemia, and even then those 
expenditures does not consider the indirect expenses such as transportation and 
escort the patient to the hospital and absence from work.  
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OBJECTIVES: To determine the components and the costs of an exercised-based 
rehabilitation program for patients with chronic systolic HF, from the point of 
view of the provider of the service. METHODS: Systematic review of the 
literature and expert consensus. Identification of components of HF 
rehabilitation programs, based on the literature, and Delphi rounds of experts for 
consensus. Only variable costs associated with the components of the program 
were estimated, based on the Colombian 256 agreement of 2001 (the Colombian 
norm that set the tariff for reimbursement for health care services) plus 23%, 
30%, or 48%, to approximate the range of costs in current (2012) health care 
package negotiations in Colombia between providers and payers. For 2012, 
US$1=COL$1,783. RESULTS: Based on expert consensus of cardiologists and 
physical therapists, 18 components of the rehabilitation program were identified. 
After the second round, over 80% agreement was obtained for the remaining 
three components, and an additional component was identified. After the third 
round, consensus was obtained for a program of 36 rehabilitation sessions and 
19 components. With the base-case scenario of agreement 256 plus 30%, the cost 
per session of the program was inversely proportional to the number of patients 
in each session: COL $96,903 for one patient, and COL $11,623 for 15 patients. For 
a program with 10 patients per session, the costs of a program may range from 
COL$ 471,130 to COL $656,554, depending on the agreement type. CONCLUSIONS: 
Agreement is critical to unify criteria on the components of a rehabilitation 
program that is both effective and safe for patients with HF. From the point of 
view of the provider, variable costs associated with implementation are sensitive 
to the number of patients per session. This study should set the basis for the 
estimation of the cost-effectiveness of rehabilitation programs in heart failure.  
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OBJECTIVES: Although the Advisory Committee for Immunization Practices 
(ACIP) and other organizations recommend annual influenza vaccination for 
cardiovascular disease patients (CVD), the vaccination rate is low in this risk 
group. Economic assessment of vaccination will aid public officials plan 
campaigns to increase coverage. METHODS: We estimated using a Monte Carlo 
(probabilistic) spreadsheet-based decision tree, the cost-effectiveness of 
vaccination to prevent hospitalization and death in all 27.1 million CVD patients 
in the US. We then estimated the benefit-cost ratios (BCR) associated with 
hospitalization and death averted by increasing coverage rates by 10% in all 
adult CVD patients from the current rates of 45% and 65% (for ages <65 years and 
≥65 years, respectively). Finally, we estimated the BCR associated with reaching 
the healthy people 2020 goal of vaccinating 90% of person’s ≥65 years and 80% of 
adults’ <65 years. We obtained treatment cost data from Marketscan database 
(2005-2010) and epidemiological data from the literature. We performed the 
analysis from the health care perspective including only cost associated with 
hospitalization and vaccination and reporting median cost values. RESULTS: 
Vaccination of all 27.1 million CVD patients’ would result in the following: 20,738 
(S.D 48,387)) quality-adjusted life years (QALY) saved, $10,107 (95% CI: cost-
savings (CS) to $70,554) / QALY saved, $31,563 (CI: CS to $151,900)/ hospitalization 
averted, and $76,588 (CI: CS to $534,658)/ premature death averted. The base case 
BCR is 0.52. A 10% increase in vaccination rate costing $41.2million (S.D $7.2 
million) would result in hospitalization-related savings of $28 million (S.D. $165 
million) (BCR=0.68). Achieving healthy 2020 goal would cost $257 million (S.D. $45 
million) and result in $ 216 million (S.D. $1.4 billion) hospitalization savings 
(BCR=0.84). CONCLUSIONS: Increasing vaccination coverage rate among CVD 
patients will avert hospitalization and most likely deaths, but with variability in 
economic impact.  
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OBJECTIVES: Erectile dysfunction is a common male sexual disorder worldwide. 
Three oral medications – sildenafil, vardenafil, and tadalafil – have been used to 
treat erectile dysfunction. This study aimed to conjointly evaluate the 
therapeutic risks and benefits of the three medications to assist decision making 
of prescribing from the perspective of both physicians and patients. METHODS: 
A decision model was created to compare the risk-benefit of the aforementioned 
medications. Using published meta-analysis data, we performed a probabilistic 
Monte Carlo simulation to estimate the joint distribution of each type of adverse 
event (i.e., risk; categories included: any adverse event, serious cardiovascular 
(CV) events, headache, flushing, and dyspepsia) and effectiveness (defined as 
proportion of patients with improved erections). The incremental risk-benefit 
ratios (ICBRs) were calculated, and the results were illustrated by incremental 
risk–benefit planes. To account for differential risk preferences across patients, 
the results were also illustrated using risk–benefit acceptability curves and net-
benefit curves. RESULTS: When risk was defined as having any adverse event, 
serious CV event, or headache, sildenafil was dominated by vardenafil (ICBR= 
-1.00, -0.20, and -3.20, respectively); tadalafil showed increasing risk and benefit 
as compared to vardenafil (ICBR=0.83, 0.03, and 0.13, respectively). Tadalafil 
dominated sildenafil and vardenafil when balancing between the risk of 
flushing/dyspepsia and the drug efficacy. CONCLUSIONS: Based on patients’ 
concern of various categories of adverse events and assuming negligible concern 
over medical costs, vardenafil or tadalafil may be preferred over sildenafil.  
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OBJECTIVES: In 2011, investments in continuing medical education (CME) 
exceeded $2 billion. Few studies report the economic impact of CME activities. 
Greater understanding of the economic value of CME assists stakeholders and 
health care cost payers in resource allocation. It is not feasible to obtain patient-
level data after each CME activity. We developed a model to estimate the 
potential health care cost savings associated with CME activity outcomes. 
METHODS: We evaluated data from a certified CME symposium for surgeons 
that reviewed the Society for Thoracic Surgeons (STS) blood conservation 
guidelines. The activity promoted prevention of bleeding-related complications 
(BRCs). We estimated the potential savings of averted BRCs from the provider 
perspective predicted by participants' self-reported commitment to change 
(CTC). Model parameter estimates were from: 1) costs of BRCs in 103,826 cardiac 
operations; 2) costs of reoperation for bleeding in 133,001 coronary artery bypass 
graft surgeries; 3) operative volume from the STS workforce report. The base case 
was 3 in 10 participants preventing one BRC in 2% of operations over 1 year. 
Probabilistic sensitivity analysis (PSA) using second-order Monte Carlo 
simulations was used to model parameter uncertainty. Results were 
standardized to 2012 $US using the medical care component of the Consumer 
Price Index. RESULTS: 93.8% of participants (n=133) reported CTC, a validated 
measure of behavior change. For BRCs, the savings for the base case was 
$1,500,112. PSA estimated the mean savings as $1,502,769 (95% CI, $869,860–
$2,359,068). For reoperation for bleeding, the savings for the base case was 
$2,974,497. PSA estimated the mean savings as $2,959,117 (95% CI, $1,135,992–
$5,566,487). CONCLUSIONS: Plausible economic estimates suggest that CME-
related learning favorably impacting clinical practice yields substantial cost 
savings. Model prediction of averted costs associated with CME allows 
estimation of the economic impact on surgical outcomes in the absence of 
patient-level outcomes data related to CME activities.  
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OBJECTIVES: Advanced heart failure (HF) is a leading cause of death in developed 
countries with a one-year mortality rate estimated at 40% after the first 
hospitalization. In France, HF affects 150 000 persons with annual costs of up to 
1,6 billon euros. Cardiac transplantation is the most effective treatment. 
However, because of a limited donor organ supply, innovative technics as left 
ventricular assist devices (LVAD) are developed as bridge to transplantation for 
over 10 years. The aim of this study is to assess the medical and economic 
consequences of LVAD in adults with advanced HF in France. METHODS: 
Between April 2008 and November 2011, 55 patients were included in this study 
in 14 French hospitals and were followed during one year after implantation. The 
primary medical outcome was the discharge at home and secondary medical 
outcome was the final situation of patient. This prospective economic analysis 
adopted the health care payer’s perspective and took into account direct medical 
and non-medical costs. RESULTS: This intermediate analysis included 21 
patients. LVAD used are HeartMate II (n=12), Jarvik 2000 (n=8) and Ventrassist 
(n=1). On the 21 patients, 15 were discharged at home spending an average of 265 
days (8.7 months) at home. During the follow-up period, 4 patients were 
transplanted, 6 patients died, and 11 were still on device at home. The mean 
total cost per implanted patient was €161,843 (±36,533). The device and initial 
hospitalization are the most important costs and represent respectively 58% and 
30% of the total cost. One day spent at home costs in average €59 CONCLUSIONS: 
Continuous-flows LVAD represent a costly strategy in the HF treatment. 
However, LVAD allow the patient to be discharged at home instead of awaiting 
heart transplantation at hospital.  
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